Compare Bank of America Corp (BAC) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of America Corp vs Viatris Inc — how do they compare? Bank of America Corp trades at $61.6 (market cap $425.43B), while Viatris Inc trades at $16.64 (market cap $18.99B). The key difference: Bank of America Corp is far larger — about 22.4× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.94%). Which is the better fit depends on your goals.
| BAC | VTRS | |
|---|---|---|
Market Cap | $425.43B | $18.99B |
Volume | 55,637,172 | — |
Sector | Financials | Health |
52-Week High | $60.62 | $17.39 |
52-Week Low | $44.92 | $8.74 |
Dividend Yield | 1.85% | 2.94% |
Enterprise Value | — | $31.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bank of America (BAC) trades at $59.50, down 0.28% today, with a bullish technical outlook and strong fundamental support. The stock shows consistent earnings beats, with Q2 2026 EPS of $1.21 exceeding the $1.13 estimate. Revenue growth accelerated to $113.1 billion in 2025, and the P/E ratio of 14 remains attractive. Recent news highlights strategic partnerships and hiring initiatives, reinforcing long-term growth prospects.
BAC presents a favorable investment case with solid profitability, a 64.8% analyst buy rating, and a consensus price target of $63.79 offering 7.2% upside. Risks include sensitivity to interest rates and macroeconomic volatility, but the bank's deposit franchise and capital flexibility provide resilience. The stock is well-positioned for steady appreciation amid supportive technicals and fundamental strength.
Viatris (VTRS) trades at $16.39, up 0.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, with improving cash flow trends and a consensus price target of $20. Recent positive Phase 3 results for VR-205 and FDA acceptance of a new drug application highlight pipeline progress.
The outlook is mixed: strong analyst buy ratings and a 22% upside to target suggest value, but profitability challenges and high debt pose risks. Investors should weigh the potential from pipeline catalysts against ongoing margin pressure and competitive threats in the generic drug space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of America Corp
Bank of America Corporation operates as a financial holding company. The Company offers saving accounts, deposits, mortgage and construction loans, cash and wealth management, certificates of deposit, investment funds, credit and debit cards, insurance, mobile, and online banking services. Bank of America serves customers worldwide.
Read more on BAC →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
